• Poisoning/overdose

Kayexalate Generic Name & Formulations

General Description

Sodium polystyrene sulfonate; pwd; sodium content 4.1mEq/g.

Pharmacological Class

Cation exchange resin.

How Supplied

Jar (453g)—1

Kayexalate Indications



Limitations of Use

Not for treating life-threatening hyperkalemia due to its delayed onset of action.

Kayexalate Dosage and Administration


See full labeling. Oral: give in an upright position; 15g as a suspension 1–4 times daily. Rectal enema: 30–50g in 100mL every 6hrs.


See full labeling. 1g per 1mEq of potassium as basis of calculation may be used.

Kayexalate Contraindications


Obstructive bowel disease. Neonates with reduced gut motility.

Kayexalate Boxed Warnings

Not Applicable

Kayexalate Warnings/Precautions


Avoid in patients at risk for constipation/impaction (eg, history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, bowel obstruction); discontinue if constipation develops. Post-surgery: avoid if have not had a bowel movement. CHF, hypertension, edema: monitor for fluid overload. Risk of aspiration. Monitor electrolytes (eg, potassium, calcium, magnesium). Neonates: do not give by oral route. Infants.

Kayexalate Pharmacokinetics

See Literature

Kayexalate Interactions


Increased risk of intestinal necrosis with concomitant sorbitol; not recommended. Separate dosing by ≥3hrs before or ≥3hrs after other oral drugs (6hrs in patients with gastroparesis). Increased risk of systemic alkalosis with nonadsorbable cation-donating antacids and laxatives. Reduces absorption of thyroxine, lithium.

Kayexalate Adverse Reactions

Adverse Reactions

Anorexia, constipation, diarrhea, fecal impaction, GI concretions (bezoars), ischemic colitis, nausea, vomiting; intestinal necrosis, electrolyte disturbances.

Kayexalate Clinical Trials

See Literature

Kayexalate Note

Not Applicable

Kayexalate Patient Counseling

See Literature